



YOU WORK IN NEVERLAND

NEVER ENOUGH TIME. NEVER A RISK-FREE MOMENT.
AND DEFINITELY NO ROOM FOR ERROR.

More than ever, the land of never requires LifeShield®—
Hospira's premier line of IV safety equipment.

Engineered specifically for contamination control,
needlestick prevention and heightened performance in
IV drug delivery, LifeShield® TKO™ bonded with CLAVE®
helps hospitals take on IV risk with confidence.

LIFESHIELD®
PREMIER IV SAFETY SYSTEM

IT'S TIME TO INVEST IN IV SAFETY. TALK TO YOUR HOSPIRA REPRESENTATIVE.



LIFESHIELD
TKO BONDED WITH CLAVE

Hospira, Inc., 275 North Field Drive, Lake Forest, IL 60045 P09-2020 Printed in the USA.

CLAVE®

CHEMOCLAVE®

TKO™

EFFECT-IV™

SPIROS™

MICROCLAVE®

CLC2000®

BLUNT CANNULA

GENIE™

MORE THAN EVER

NEVERLAND

REQUIRES LIFESHIELD® TKO™ BONDED WITH CLAVE®

IN NEVERLAND

Hospital-acquired infections (HAIs) are dangerous, prevalent and costly

- Fourth largest killer in the US¹
- 1.7 million infections annually²
- Cost hospitals \$30.5 billion each year¹

Most HAIs are associated with catheter-related bloodstream infections (CRBSIs)³

- ≈250,000 CRBSIs occur each year⁴
- Extended hospital length of stay—up to 20 days⁵
- \$45,000 per episode⁴

IT'S TIME TO INVEST IN IV SAFETY.

LIFESHIELD TKO BONDED WITH CLAVE MAKES IV RISKS MORE MANAGEABLE

- Bonded system minimizes accidental disconnect⁶
- Enhanced IV functionality decreases risk of occlusion⁶
- Proven compatibility optimizes delivery of care⁶



Swabbable valve bonded to anti-reflux device. Features high flow rates. Low residual volume. And virtually no blood retrograde. Convenience and safety combined with optimal blood reflux management.

PRODUCT	LIST NUMBER
LifeShield TKO 4 + CLAVE	18034-01

TKO is not a trademark of Hospira, Inc. CLAVE is not a registered trademark of Hospira, Inc.

CALL 1-877-946-7747 FOR YOUR FREE EVALUATION.

LIFESHIELD®
PREMIER IV SAFETY SYSTEM

References: 1. McCaughey B. Unnecessary deaths: the human and financial costs of hospital infections. 2008. <http://www.hospitalinfection.org/costofinfection.shtml>. Accessed November 6, 2008. 2. Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating health care-associated infections and deaths in US hospitals, 2002. *Public Health Rep.* 2007;122(2):160-166. 3. Slater F. Cost-effective infection control success story: a case presentation. *Emerg Infect Dis.* 2001;7(2):293-294. 4. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. *MMWR.* 2002;51(RR10):1-26. <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5110a1.htm>. August 9, 2002. Accessed May 4, 2009. 5. Shorr AF, Humphreys CW, Helman DL. New choices for central venous catheters: potential financial implications. *Chest.* 2003;124(1):275-284. 6. Data on file. Hospira, Inc.